Australian Clinical Labs (ASX:ACL) - Hisse Senedi Fiyatı, Haberler ve Analizler

ACL Stoklara Genel Bakış

Australian Clinical Labs Limited Avustralya'da patoloji teşhis hizmetleri sunmaktadır.

ACL temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	1/6
Finansal Sağlık	4/6
Temettüler	2/6

Ödüller

Adil değer tahminimizden 40.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 15.94% oranında artması öngörülüyor

Risk Analizi

3.36% temettüsü kazançlar tarafından iyi karşılanmıyor

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Kar marjları (3.4%) geçen yılın (5.2%) altında

Australian Clinical Labs Limited Rakipler

Healthia

ASX:HLA

AU$252.1m

SILK Laser Australia

ASX:SLA

AU$177.4m

Apiam Animal Health

ASX:AHX

AU$94.0m

Sonic Healthcare

ASX:SHL

AU$12.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Australian Clinical Labs
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$3.57
52 Haftanın En Yüksek Seviyesi	AU$3.86
52 Haftanın En Düşük Seviyesi	AU$2.14
Beta	1.18
11 Aylık Değişim	-1.65%
3 Aylık Değişim	45.71%
1 Yıllık Değişim	35.74%
33 Yıllık Değişim	-19.05%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	4.39%

Son Haberler & Güncellemeler

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Sep 02

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Hissedar Getirileri

	ACL	AU Healthcare	AU Pazar
7D	-2.2%	-2.8%	-0.6%
1Y	35.7%	-1.5%	16.5%

Getiri vs. Endüstri: ACL geçen yıl % -1.5 oranında getiri sağlayan Australian Healthcare sektörünü aştı.

Getiri vs Piyasa: ACL geçen yıl % 16.5 oranında getiri sağlayan Australian Piyasasını aştı.

Fiyat Oynaklığı

Is ACL's price volatile compared to industry and market?
ACL volatility
ACL Average Weekly Movement	5.2%
Healthcare Industry Average Movement	5.3%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.8%
10% least volatile stocks in AU Market	3.6%

İstikrarlı Hisse Senedi Fiyatı: ACL son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ACL 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2020	4,900	Melinda McGrath	www.clinicallabs.com.au

Australian Clinical Labs Limited, Avustralya'da patoloji teşhis hizmetleri sunmaktadır. Şirket, rutin patoloji testi, gelişmiş moleküler genetik testi, uyumlu NIPT ve ilk trimester taraması, genetik taşıyıcı taraması, kimyasal patoloji, histopatoloji ve sitopatoloji; hematoloji, alerji ve immünoloji; seroloji ve mikrobiyoloji; ve bulaşıcı moleküler test, kardiyak test hizmetleri, fonksiyonel patoloji, veteriner patolojisi ve ticari uyuşturucu ve alkol test hizmetlerini içeren bir dizi hizmet sunmaktadır. Hizmetini özel ve kamu hastanelerine sunmaktadır.

Australian Clinical Labs Limited Temel Bilgiler Özeti

Australian Clinical Labs'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ACL temel i̇stati̇sti̇kler
Piyasa değeri	AU$715.75m
Kazançlar(TTM)	AU$23.93m
Gelir(TTM)	AU$696.37m

29.8x

F/K Oranı

1.0x

P/S Oranı

ACL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ACL gelir tablosu (TTM)
Gelir	AU$696.37m
Gelir Maliyeti	AU$442.37m
Brüt Kâr	AU$254.00m
Diğer Giderler	AU$230.07m
Kazançlar	AU$23.93m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Feb 26, 2025

Hisse başına kazanç (EPS)	0.12
Brüt Marj	36.48%
Net Kâr Marjı	3.44%
Borç/Özkaynak Oranı	31.0%

ACL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

3.4%

Mevcut Temettü Verimi

100%

Ödeme Oranı

ACL Stoklara Genel Bakış

Ödüller

Risk Analizi

Australian Clinical Labs Limited Rakipler

ASX:HLA

AU$252.1m

ASX:SLA

AU$177.4m

ASX:AHX

AU$94.0m

ASX:SHL

AU$12.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Hissedar Getirileri